UPDATE: Mylan Launches First Generic Version of Doryx® 150 mg
Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.
Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx® 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.
Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.